Profile data is unavailable for this security.
About the company
Agentix Corp. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic agents for the treatment of metabolic diseases like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its pipeline includes AGTX-2004 and AGTX-2003. AGTX-2004 is a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM). AGTX-2003 is a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease. The Company is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is the regulatory system which governs metabolism. The Company’s wholly owned subsidiaries include GSL Healthcare, Inc., Agentix Australia Pty Ltd, and Applied Biopharma LLC.
- Revenue in USD (TTM)0.00
- Net income in USD-1.01m
- Incorporated2013
- Employees--
- LocationAgentix Corp32932 PACIFIC COAST HIGHWAY, #14-254DANA POINT 92629United StatesUSA
- Phone+1 (321) 229-2014
- Websitehttps://agentixcorp.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scisparc Ltd | 0.00 | -6.96m | 532.75k | 3.00 | -- | 21.87 | -- | -- | -1.22 | -1.51 | 0.00 | 0.0344 | 0.00 | -- | -- | 0.00 | -92.51 | -69.39 | -152.41 | -111.07 | -- | -- | -- | -527.17 | -- | -- | 0.9371 | -- | 113.73 | -- | -97.61 | -- | -- | -- |
| ITonis Inc | 0.00 | -1.17m | 533.19k | -- | -- | -- | -- | -- | -0.0012 | -0.0012 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -187.63 | -- | -1,169.36 | -- | -- | -- | -- | -- | -- | -0.8999 | -- | -- | -- | -- | -506.86 | -- | -- | -- |
| Evofem Biosciences Inc | 16.01m | 47.49m | 595.78k | 37.00 | 0.001 | -- | 0.0125 | 0.0372 | -5.92 | -5.92 | 0.0826 | -1.36 | 0.935 | 1.72 | 2.73 | 432,756.80 | 295.02 | -211.64 | -- | -- | 63.65 | -- | 315.54 | -1,031.55 | 0.0757 | -2.91 | -- | -- | 8.20 | -- | 164.08 | -- | -10.59 | -- |
| Neutra Corp | 17.40k | -474.98k | 729.47k | -- | -- | -- | -- | 41.92 | -0.0002 | -0.0002 | 0.00001 | -0.0003 | 0.2786 | 0.4126 | -- | -- | -758.75 | -682.94 | -- | -- | 46.15 | -- | -2,723.22 | -2,758.85 | 0.0009 | -14.06 | -- | -- | -26.09 | -- | 22.28 | -- | -- | -- |
| Bespoke Extracts Inc | 956.86k | -1.36m | 894.83k | 10.00 | -- | -- | -- | 0.9352 | -0.1331 | -0.1331 | 0.0941 | -0.194 | 2.29 | 20.10 | 21.36 | 95,686.00 | -325.13 | -- | -- | -- | 45.50 | -- | -141.75 | -- | 0.0482 | -53.38 | -- | -- | 22,933.72 | -- | 63.98 | -- | -- | -- |
| InVitro International | 716.89k | 6.22k | 910.39k | 16.00 | 114.29 | 1.25 | -- | 1.27 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
| Gold River Productions Inc. | -100.00bn | -100.00bn | 961.91k | 1.00k | -- | 1.48 | -- | -- | -- | -- | -- | 0.0005 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.11 | -- | -- | -- |
| Agentix Corp | 0.00 | -1.01m | 1.05m | -- | -- | -- | -- | -- | -0.0253 | -0.0253 | 0.00 | -0.071 | 0.00 | -- | -- | -- | -907.08 | -- | -- | -- | -- | -- | -- | -- | -- | -96.41 | -- | -- | -- | -- | -- | -- | -- | -- |
| PainReform Ltd | 0.00 | -12.54m | 1.14m | 6.00 | -- | 0.4606 | -- | -- | -7.77 | -7.77 | 0.00 | 0.9988 | 0.00 | -- | -- | 0.00 | -158.88 | -55.47 | -222.89 | -68.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.28 | -- | -- | -- |
| Vestiage Inc | 0.00 | -21.76k | 1.32m | 0.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0011 | 0.00 | -- | -- | -- | -4,945.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -102.30 | -- | -- | -- |
